Enhanced treatment regimens using mTor inhibitors
AssigneeIntellikine LLC
InventorsYi Liu, Lynne Bui, Michael Martin, Troy Edward Wilson, Christian Rommel
Life of this patent
Estimating the term…
Abstract
The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.
Claims21
A method of treating cancer in a subject in need thereof, comprising administering an mTorC1/mTorC2 inhibitor to said subject according to an intermittent regimen which comprises at least one cycle in which the mTorC1/mTorC2 inhibitor is administered for at least 1 day, followed by an intermission in which the mTorC1/mTorC2 inhibitor is not administered for at least 1 day;
- wherein the cancer is renal cancer, renal cell carcinoma, colorectal cancer, uterine sarcoma, endometrial uterine cancer, endometrial cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, fibrosarcoma, pancreatic cancer, liver cancer, melanoma, leukemia, myeloma, nasopharyngeal cancer, prostate cancer, lung cancer, glioblastoma, bladder cancer, mesothelioma, head cancer, or neck cancer;
- wherein the mTorC1/mTorC2 inhibitor has the Formula:
- or a pharmaceutically acceptable salt thereof, wherein:
- E2 is H;
- X1 is N;
- X2 is N;
- W2 is NH;
- k is 1;
- R2 is H;
- and R1 is isopropyl.
Dependencies are inferred from the claim text.